Profil
Paul F.
Glidden is the founder of BioVascular, Inc. (founded in 2005) where he holds the title of Director & Vice President-Development.
He is currently working at NanoSmart Pharmaceuticals, Inc. as Vice President-Research & Development since 2012.
In his former positions, he worked as Director-Pharmacology & Toxicology at ISTA Pharmaceuticals, Inc., Vice President-Development at Angiosyn, Inc., and as Principal at Alpha Therapeutic Corp.
from 1989 to 2000.
Dr. Glidden completed his undergraduate degree at Oregon State University and obtained a doctorate degree from the University of California, Irvine.
Postes actifs de Paul F. Glidden
| Sociétés | Poste | Début |
|---|---|---|
BioVascular, Inc.
 BioVascular, Inc. Pharmaceuticals: MajorHealth Technology BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA. | Fondateur | 23/02/2010 |
NanoSmart Pharmaceuticals, Inc.
 NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | Directeur Technique/Scientifique/R&D | 24/05/2012 |
Anciens postes connus de Paul F. Glidden
| Sociétés | Poste | Fin |
|---|---|---|
Alpha Therapeutic Corp.
 Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA. | Corporate Officer/Principal | 01/01/2000 |
ISTA Pharmaceuticals, Inc.
 ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Corporate Officer/Principal | - |
Angiosyn, Inc.
 Angiosyn, Inc. Pharmaceuticals: OtherHealth Technology Angiosyn, Inc. develops pharmaceutical products for controlling angiogenesis | Corporate Officer/Principal | - |
Formation de Paul F. Glidden
| Oregon State University | Undergraduate Degree |
| University of California, Irvine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
ISTA Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Health Technology |
Angiosyn, Inc.
Angiosyn, Inc. Pharmaceuticals: OtherHealth Technology Angiosyn, Inc. develops pharmaceutical products for controlling angiogenesis | Health Technology |
Alpha Therapeutic Corp.
Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA. | Health Technology |
BioVascular, Inc.
BioVascular, Inc. Pharmaceuticals: MajorHealth Technology BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA. | Health Technology |
NanoSmart Pharmaceuticals, Inc.
NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | Health Technology |
